ダラツムマブ・ダルザレックスの世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

ダラツムマブ・ダルザレックスの市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）10％で81億8,940万米ドルに成長します。予測期間の成長は、臨床エビデンスの実証、早期治療ラインでの採用の増加、生物製剤の需要増加、患者の意識レベルの向上、血液がんの罹患率の増加、慢性疾患の有病率の上昇に起因しています。予測期間における主要動向としては、技術の進歩、新製品の上市、製品やサービスの提供、提携、M&A、放射線技術の進歩、共同研究などが挙げられます。

骨髄がんの罹患率の増加は、今後のダラツムマブ（ダルザレックス）市場の成長を促進すると予想されます。多発性骨髄腫や白血病などの骨髄がんは、骨髄から始まり、正常な身体機能を阻害する異常な血球産生を引き起こします。骨髄がん患者の増加は、人口の高齢化、検出方法の向上、環境、ライフスタイル、遺伝的影響などの要因に起因しています。ダラツムマブ（ダルザレックス）は、骨髄内の異常形質細胞を標的として排除することにより、多発性骨髄腫の治療に使用されます。例えば、2024年1月に米国がん学会は、リンパ腫8万9,190例、骨髄腫3万5,780例を予測しているが、それぞれ2022年には8万9,010例、3万4,470例でした。このような骨髄がん罹患率の上昇が、ダラツムマブ（ダルザレックス）市場の拡大を後押ししています。

生物製剤や標的療法の採用拡大が、ダラツムマブ（ダルザレックス）市場の成長をさらに促進すると予想されます。標的療法は、薬剤やその他の物質を用いて、がんなどの疾患の進行に関与する分子を特異的に特定し、攻撃するものです。生物製剤や標的治療の使用が増加している背景には、慢性疾患の有病率の上昇と、より個別化された効果的な治療を可能にする精密医療の進歩があります。ダラツムマブは、多発性骨髄腫の悪性形質細胞に高発現するタンパク質であるCD38を特異的に標的とするため、これらの標的療法の一部です。例えば、2023年12月、先進治療センター（ATTC）は、2022年の先進治療への年間投資額が31％増加し、英国は世界の商業的先進治療医薬品（ATMP）臨床検査の14％を占めると報告しました。このような生物製剤や標的療法の採用拡大が、ダラツムマブ（ダルザレックス）市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のダラツムマブ・ダルザレックス：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のダラツムマブ・ダルザレックス市場：成長率分析
• 世界のダラツムマブ・ダルザレックス市場の実績：規模と成長、2019～2024年
• 世界のダラツムマブ・ダルザレックス市場の予測：規模と成長、2024～2029年、2034年
• 世界のダラツムマブ・ダルザレックス：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のダラツムマブ・ダルザレックス市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 100mg注射剤
• 400mg注射剤
• 世界のダラツムマブ・ダルザレックス市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬局
• 病院
• その他
• 世界のダラツムマブ・ダルザレックス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 濾胞性リンパ腫
• マントル細胞リンパ腫
• 多発性骨髄腫
• びまん性大細胞型B細胞リンパ腫
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のダラツムマブ・ダルザレックス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のダラツムマブ・ダルザレックス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ダラツムマブ・ダルザレックス市場：競合情勢
• ダラツムマブ・ダルザレックス市場：企業プロファイル
  • Genmab A/S
  • Janssen BIoTech Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ダラツムマブ・ダルザレックス市場、2029年：新たな機会を提供する国
• ダラツムマブ・ダルザレックス市場、2029年：新たな機会を提供するセグメント
• ダラツムマブ・ダルザレックス市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Daratumumab, also known by its brand name Darzalex, is a monoclonal antibody used in the treatment of certain cancers, primarily multiple myelomas. It is designed to target and bind to CD38, a protein highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of daratumumab (Darzalex) are 100 mg injection and 400 mg injection. The 100 mg injection refers to a dose of the medication administered via injection, containing 100 milligrams (mg) of the active ingredient. These drugs are distributed through various channels, including pharmacies, hospitals, and other medical distribution networks. They are used in the treatment of conditions such as follicular lymphoma, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma, and others.

The daratumumab or darzalex market research report is one of a series of new reports from The Business Research Company that provides daratumumab or darzalex market statistics, including daratumumab or darzalex industry global market size, regional shares, competitors with a daratumumab or darzalex market share, detailed daratumumab or darzalex market segments, market trends and opportunities, and any further data you may need to thrive in the daratumumab or darzalex industry. This daratumumab or darzalex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The daratumumab or darzalex market size is expected to see rapid growth in the next few years. It will grow to $8,189.4 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing clinical evidence demonstrating, rising adoption in earlier treatment lines, increasing the demand for biologics, increasing patient awareness levels, growing incidence of blood cancer, and rising prevalence of chronic diseases. Major trends in the forecast period include technological advancements, new product launches, offerings of products and/or services, partnerships, mergers and acquisitions, advancements in radiation technologies, and collaborations.

The increasing incidence of bone marrow cancers is expected to drive the growth of the daratumumab (Darzalex) market in the future. Bone marrow cancers, such as multiple myeloma and leukemia, begin in the bone marrow, causing abnormal blood cell production that disrupts normal body functions. The rise in bone marrow cancer cases can be attributed to factors like an aging population, better detection methods, and environmental, lifestyle, and genetic influences. Daratumumab (Darzalex) is used to treat multiple myeloma by targeting and eliminating abnormal plasma cells in the bone marrow. For example, in January 2024, the American Cancer Society projected 89,190 lymphoma cases and 35,780 myeloma cases, compared to 89,010 and 34,470 in 2022, respectively. This rise in bone marrow cancer incidence is driving the expansion of the daratumumab (Darzalex) market.

The growing adoption of biologics and targeted therapies is expected to further fuel the growth of the daratumumab (Darzalex) market. Targeted therapies use drugs or other substances to specifically identify and attack molecules involved in disease progression, such as cancer. The increasing use of biologics and targeted therapies is driven by the rising prevalence of chronic diseases and advancements in precision medicine, which allow for more personalized and effective treatments. Daratumumab is part of these targeted therapies, as it specifically targets CD38, a protein highly expressed on malignant plasma cells in multiple myeloma. For instance, in December 2023, the Advanced Therapy Treatment Centers (ATTC) reported a 31% increase in annual investments in advanced therapies in 2022, with the UK accounting for 14% of global commercial advanced therapy medicinal product (ATMP) clinical trials. This growing adoption of biologics and targeted therapies is contributing to the growth of the daratumumab (Darzalex) market.

A key trend in the daratumumab (Darzalex) market is the shift toward early intervention strategies, such as combination therapies, to enhance the effectiveness of treating multiple myeloma and other cancers. Combination therapies use two or more drugs with different mechanisms of action to improve efficacy, reduce resistance, and potentially lower adverse effects compared to monotherapy. For example, in July 2024, Johnson & Johnson received U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT). This approval introduces a quadruplet therapy option for patients at initial diagnosis, potentially improving treatment outcomes.

Major players operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in daratumumab or darzalex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the daratumumab or darzalex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The daratumumab or darzalex market consists of sales of darzalex faspro, darzalex injection, dexamethasone, and pomalidomide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Daratumumab Or Darzalex Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on daratumumab or darzalex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for daratumumab or darzalex ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The daratumumab or darzalex market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: 100Mg Injection; 400Mg Injection
• 2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
• 3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
• Companies Mentioned: Genmab A/S; Janssen Biotech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Daratumumab Or Darzalex Market Characteristics

3. Daratumumab Or Darzalex Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Daratumumab Or Darzalex Market Trends And Strategies

5. Daratumumab Or Darzalex Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Daratumumab Or Darzalex Growth Analysis And Strategic Analysis Framework

• 6.1. Global Daratumumab Or Darzalex PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Daratumumab Or Darzalex Market Growth Rate Analysis
• 6.4. Global Daratumumab Or Darzalex Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Daratumumab Or Darzalex Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Daratumumab Or Darzalex Total Addressable Market (TAM)

7. Global Daratumumab Or Darzalex Market Pricing Analysis & Forecasts

8. Daratumumab Or Darzalex Market Segmentation

• 8.1. Global Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100Mg Injection
• 400Mg Injection
• 8.2. Global Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Hospital
• Other Distribution Channels
• 8.3. Global Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Diffuse Large B Cell Lymphoma
• Other Applications

9. Global Daratumumab Or Darzalex Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Daratumumab Or Darzalex Market Regional And Country Analysis

• 10.1. Global Daratumumab Or Darzalex Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Daratumumab Or Darzalex Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Daratumumab Or Darzalex Market

• 11.1. Asia-Pacific Daratumumab Or Darzalex Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Daratumumab Or Darzalex Market

• 12.1. China Daratumumab Or Darzalex Market Overview
• 12.2. China Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Daratumumab Or Darzalex Market

• 13.1. India Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Daratumumab Or Darzalex Market

• 14.1. Japan Daratumumab Or Darzalex Market Overview
• 14.2. Japan Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Daratumumab Or Darzalex Market

• 15.1. Australia Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Daratumumab Or Darzalex Market

• 16.1. South Korea Daratumumab Or Darzalex Market Overview
• 16.2. South Korea Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Daratumumab Or Darzalex Market

• 17.1. Western Europe Daratumumab Or Darzalex Market Overview
• 17.2. Western Europe Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Daratumumab Or Darzalex Market

• 18.1. UK Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Daratumumab Or Darzalex Market

• 19.1. Germany Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Daratumumab Or Darzalex Market

• 20.1. France Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Daratumumab Or Darzalex Market

• 21.1. Eastern Europe Daratumumab Or Darzalex Market Overview
• 21.2. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Daratumumab Or Darzalex Market

• 22.1. North America Daratumumab Or Darzalex Market Overview
• 22.2. North America Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Daratumumab Or Darzalex Market

• 23.1. USA Daratumumab Or Darzalex Market Overview
• 23.2. USA Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Daratumumab Or Darzalex Market

• 24.1. Canada Daratumumab Or Darzalex Market Overview
• 24.2. Canada Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Daratumumab Or Darzalex Market

• 25.1. South America Daratumumab Or Darzalex Market Overview
• 25.2. South America Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Daratumumab Or Darzalex Market

• 26.1. Middle East Daratumumab Or Darzalex Market Overview
• 26.2. Middle East Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Daratumumab Or Darzalex Market

• 27.1. Africa Daratumumab Or Darzalex Market Overview
• 27.2. Africa Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Daratumumab Or Darzalex Market Competitive Landscape And Company Profiles

• 28.1. Daratumumab Or Darzalex Market Competitive Landscape
• 28.2. Daratumumab Or Darzalex Market Company Profiles
  • 28.2.1. Genmab A/S Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Daratumumab Or Darzalex Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Daratumumab Or Darzalex Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Daratumumab Or Darzalex Market

32. Recent Developments In The Daratumumab Or Darzalex Market

33. Daratumumab Or Darzalex Market High Potential Countries, Segments and Strategies

• 33.1 Daratumumab Or Darzalex Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Daratumumab Or Darzalex Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Daratumumab Or Darzalex Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer